Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Silence Therapeutics (SLN)

Silence Therapeutics PLC
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SLN
DateTimeSourceHeadlineSymbolCompany
08/04/202416:48Business WireSilence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)NASDAQ:SLNSilence Therapeutics PLC
13/03/202411:05Business WireSilence Therapeutics Reports Full Year 2023 Financial Results and Recent Business HighlightsNASDAQ:SLNSilence Therapeutics PLC
13/03/202411:03IH Market NewsMixed Futures Amidst Quiet Economic Schedule; Oil Prices ClimbNASDAQ:SLNSilence Therapeutics PLC
13/03/202411:00Business WireSilence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)NASDAQ:SLNSilence Therapeutics PLC
28/02/202413:00Business WireSilence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024NASDAQ:SLNSilence Therapeutics PLC
23/02/202413:12Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SLNSilence Therapeutics PLC
23/02/202413:00Business WireSilence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 TrialNASDAQ:SLNSilence Therapeutics PLC
14/02/202414:54Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SLNSilence Therapeutics PLC
14/02/202413:55Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SLNSilence Therapeutics PLC
05/02/202413:00Business WireSilence Therapeutics Announces Oversubscribed $120 Million Private PlacementNASDAQ:SLNSilence Therapeutics PLC
31/01/202412:00Business WireSilence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:SLNSilence Therapeutics PLC
01/12/202312:00Business WireSilence Therapeutics Strengthens Executive Leadership Team with Key AppointmentsNASDAQ:SLNSilence Therapeutics PLC
14/11/202312:00Business WireSilence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial ResultsNASDAQ:SLNSilence Therapeutics PLC
08/11/202312:00Business WireSilence Therapeutics to Present at Jefferies London Healthcare ConferenceNASDAQ:SLNSilence Therapeutics PLC
01/11/202311:00Business WireSilence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular DiseaseNASDAQ:SLNSilence Therapeutics PLC
26/09/202312:00Business WireSilence Therapeutics to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines ConferenceNASDAQ:SLNSilence Therapeutics PLC
06/09/202312:00Business WireSilence Therapeutics to Participate in September Investor ConferencesNASDAQ:SLNSilence Therapeutics PLC
29/08/202321:01Edgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:SLNSilence Therapeutics PLC
16/08/202312:00Business WireSilence Therapeutics Reports Second Quarter 2023 ResultsNASDAQ:SLNSilence Therapeutics PLC
01/08/202321:31Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SLNSilence Therapeutics PLC
11/07/202312:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SLNSilence Therapeutics PLC
11/07/202312:00Business WireSilence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma CollaborationNASDAQ:SLNSilence Therapeutics PLC
31/05/202312:00Business WireSilence Therapeutics to Present at the Jefferies Healthcare ConferenceNASDAQ:SLNSilence Therapeutics PLC
16/05/202321:02Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:SLNSilence Therapeutics PLC
16/05/202321:00Business WireSilence Therapeutics Reports First Quarter 2023 ResultsNASDAQ:SLNSilence Therapeutics PLC
04/05/202312:00Business WireSilence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca CollaborationNASDAQ:SLNSilence Therapeutics PLC
01/05/202312:32Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:SLNSilence Therapeutics PLC
01/05/202312:00Business WireSilence Therapeutics Completes Enrollment in Phase 2 Study of Zerlasiran (SLN360) in Subjects with Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease EventsNASDAQ:SLNSilence Therapeutics PLC
25/04/202312:00Business WireSilence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Investor ConferenceNASDAQ:SLNSilence Therapeutics PLC
04/04/202312:00Business WireSilence Therapeutics Announces Publication in Blood Demonstrating Role for Iron Regulation in Polycythemia VeraNASDAQ:SLNSilence Therapeutics PLC
 Showing the most relevant articles for your search:NASDAQ:SLN